Immunoglobulin, commonly known as an antibody, is a Y-shaped protein manufactured primarily by plasma cells. Immunoglobulin is utilized by the immune system to counterbalance pathogens. Subcutaneous injections are administered as vaccines and medications including insulin and immunoglobulin. The process of administering immunoglobulin is known as immunoglobulin therapy. When immunoglobulin therapy is applied below the dermis and epidermis, or cutis, it is known as subcutaneous immunoglobulin. Subcutaneous therapy is useful as it offers a sustained rate of absorption.
Immunoglobulin replacement therapy (IRT) is the systematic care for patients with antibody deficit. Immunoglobulin replacement therapy can be of two types: subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). The choice of treatment depends upon numerous factors such as clinical symptoms, patient physiognomies, intravenous access, and possible side effects. However, subcutaneous immunoglobulin infusions for immunoglobulin replacement therapy (IRT) are more efficient, and these have a satisfactory safety profile along with good tolerance level.
Advantages of the subcutaneous route include reduced adverse effects, partial deviation in peak and trough immunoglobulin (Ig) levels, decreased need for vascular access and improved patient autonomy. Subcutaneous immunoglobulin can be administered to most patients where clinically appropriate, and with pertinent learning and follow up care. These factors are likely to fuel the growth of the global subcutaneous immunoglobulin market.
Government regulations such as approvals from the Food and Drug Administration is an essential factor likely to shape the global subcutaneous immunoglobulin market. Subcutaneous immunoglobulin requires frequent administration and some patients might need battery driven pumps for taking subcutaneous immunoglobulin. This is likely to hamper the growth of the market. However, subcutaneous immunoglobulin can be administered at home without IV (intravenous) access, thereby making it a cheap alternative as compared to intravenous immunoglobulin.
Moreover, ease of use and high movability of subcutaneous immunoglobulin makes them a preferred choice for immune deficient patient. According to a report by the National Center for Biotechnology Information, globally, over 6 million people suffer from primary immune deficiency alone. Therefore, the subcutaneous immunoglobulin market is likely to witness strong growth in the next few years.
The global resonators market can be segmented based on condition, end-user, and region. In terms of condition, the market can be segmented into primary immune deficiency and secondary immune deficiency. Primary immune deficiency accounted for the largest share of the global subcutaneous immunoglobulin market and is likely to dominate the market during the forecast period. Based on end-user, the market can be segmented into hospitals, private medical clinics, residential use, and others. Hospitals held the major share of the global market. However, the residential segment is projected to expand at a high growth rate during the forecast period driven by increasing adoption of subcutaneous immunoglobulin.
For more information on this report, fill the form @http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20594
Geographically, the global subcutaneous immunoglobulin market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America held the dominant share of the global market. Presence of key players and availability of subcutaneous immunoglobulin as well as rising adoption of advanced medical services has resulted in the dominance of this region. However, Asia Pacific is likely to grow at a substantial rate due to rise in primary immune deficiency in the region.
The global subcutaneous immunoglobulin market is characterized by the existence of a number of players. With all dealers competing to gain significant market shares, the market is very competitive in nature. Companies are competing on the basis of price and early approvals from the regulatory authorities such as the FDA.
Key players in the market include CSL Behring AG, Shire plc, Baxter International AG, Biotest AG, CUVITRU Baxalta US, Inc., Baxter Healthcare Corporation, Vivaglobin CSL, Hizentra CSL Behring AG, HYQVIA, and Behring GmbH.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453